Treatment Trials

1 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
      Description

      This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with advanced gastric or gastroesophageal junction cancer. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

      Conditions
      Adenocarcinoma of the Gastroesophageal JunctionDiffuse Gastric AdenocarcinomaGastric Intestinal Type AdenocarcinomaGastric Mixed AdenocarcinomaRecurrent Gastric Carcinoma
      Talk to us